Zhengye Biotechnology (ZYBT) vice GM Lian Wei files Form 3

Rhea-AI Filing Summary

Zhengye Biotechnology Holding Ltd officer Lian Wei has filed an initial Form 3 as a reporting person. The filing identifies Lian Wei as Vice General Manager of the company and does not list any share transactions or holdings in either common stock or derivative securities.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lian Wei

(Last) (First) (Middle)

NO.1 LIANMENG ROAD

(Street)

JILIN CITY, JILIN PROVINCE 132101

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Zhengye Biotechnology Holding Ltd [ ZYBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice General Manager

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Wei Lian	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Zhengye Biotechnology (ZYBT) Form 3 for Lian Wei report?

The Form 3 identifies Lian Wei as a reporting person and Vice General Manager of Zhengye Biotechnology Holding Ltd. It serves as an initial insider ownership statement and shows no reported transactions or derivative positions in this filing.

Did Lian Wei buy or sell any ZYBT shares in this Form 3?

No, the Form 3 for Lian Wei shows no buy or sell transactions. The transaction summary reports zero purchases, zero sales, zero exercises, and no gifts or restructuring events related to Zhengye Biotechnology Holding Ltd shares.

What is Lian Wei’s role at Zhengye Biotechnology Holding Ltd (ZYBT)?

The filing lists Lian Wei as an officer of Zhengye Biotechnology Holding Ltd with the title “Vice General Manager.” This role qualifies Lian Wei as a reporting person who must file ownership reports such as Form 3 with the SEC.

Does the ZYBT Form 3 show any derivative securities held by Lian Wei?

No, the Form 3 indicates no derivative securities for Lian Wei. The derivative summary is empty, and the transaction summary shows zero derivative transactions, meaning no options, warrants, or similar instruments are reported in this filing.

Is this ZYBT Form 3 filing considered a routine insider report?

Yes, this appears to be a routine initial Form 3 filing. It establishes Lian Wei as a reporting officer of Zhengye Biotechnology Holding Ltd and contains no material share purchases, sales, or derivative exercises in the disclosed data.